DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The disappointing findings from the $100 million National Institutes of Health (NIH) project, the first-ever prevention trial for Alzheimer’s disease, which tested an antiamyloid monoclonal antibody called crenezumab in people with the Paisa mutation, the most common cause of familial, early-onset Alzheimer’s disease.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
